Login to Your Account

BioWorld Hindsight

Earnout Pan Out? Biomarin's Deals Progressing Years Later

By Jennifer Boggs
Managing Editor

Monday, August 19, 2013

The buyout of Talon Therapeutics Inc. by Spectrum Pharmaceuticals Inc. for $11.3 million in cash up front and contingent value rights (CVRs) for up to $195 million indicate that the earnout deal remains alive and well in biotech.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription